Latest news about the TPP

May 17, 2013- Info Justice: Trans Pacific Partnership Negotiations and the Controversial Issue of Pharmaceutical Test Data Protection (links to infojutice.org)

May 16, 2013- ONG Derechos Digitales: Ex jefe de negociaciones del TPP pide una posición firme y no integrarse al tratado "de calquier manera" (links to derechosdigitales.org)

May 6, 2013- The University of Auckland Faculty of Medical and Health Sciences: Access to medicines key to reducing asthma attacks (links to fmhs.auckland.ac.nz)

April 25, 2013- El Espectator: Nueva amenaza para la libertad en internet (links to elspectador.com)

April 12, 2013- Journal of Law, Medicine and Ethics: The High Price of 'Free Trade': US Trade Agreements and Access to Medicines

April 9, 2013- The Sydney Morning Herald: Generic drugs a key to the curing of budgetary ills (links to smh.com.au)

April 1, 2013 Analysis: India’s Supreme Court Upholds Strict Patent Standards and Patients’ Right to Access to Affordable Medicines; Court dismisses unmeritorious court challenge by drug giant

April 1, 2013 Patent's defeat in India is Key Victory for Generic Drugs

April 1, 2013 Novartis Cancer-Drug Patent Denied by India Supreme Court

March 27, 2013- Truthout: TransPacific Partnership Will Undermine Democracy, Empower Transnational Corporations (links to truth-out.org)

March 17, 2013-The Nation: Avoid Mistakes of the West: Stiglitz (links to nationmultimedia.com)

March 17, 2013-Bangkok Post: Stiglitz warns not to expect a quick global recovery (links to bangkokpost.com)

March 14, 2013-IP Watch: IPRs Among "Most Challenging" Issues As TPP Talks Accelerate (links to ip-watch.org)

March 13, 2013-Inside U.S. Trade: TPP Countries Will Not Discuss New Pharmaceutical IPR Text at Next Round (links to wtonewsstand.com)

March, 2013- Doctors Without Borders Access Briefing 2013: Trading Away Health: The Trans-Pacific Partnership Agreement (links to citizen.org)

March 8, 2013-TPP Countries Poised to Revisit U.S. Access to Medicines Proposal (Inside U.S. Trade)

For older news, visit the Trans-Pacific Partnership news archive


Latest TPP Negotiation Rounds

May 15-24, 2013-Round 17: Lima, Peru

March 4-13, 2013-Round 16: Singapore

December 2-12, 2012-Round 15: Auckland, New Zealand

Sept. 6-15, 2012-Round 14: Leesburg, VA, USA

July 2-10, 2012- Round 13: San Diego, CA, USA

May 8-19, 2012-Round 12: Dallas, TX, USA

TPP Negotiations Rounds Archive

Global Access to Medicine's page on the Trans-Pacific Partnership Agreement (TPP)


The Trans-Pacific Partnership (TPP) is a proposed free trade agreement under negotiation between Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the United States and Vietnam. Leaked documents show the U.S. Trade Representative (USTR) is pressuring TPP countries to expand pharmaceutical monopoly protections and trade away access to medicines. Public Citizen and our partners envision a very different Asia-Pacific region partnership--one that advances pharmaceutical access and innovation simultaneously. Through analysis, and advocacy, we are working to spotlight public health and the knowledge economy at the negotiations and helping countries push back against Big Pharma's corporate influence.
  

What's New?


Learn More:  

Events    |    Presentations    |    Media



For more info and updates, follow us on Twitter: @PCMedsAccess.

Trans-Pacific Partnership
Country Resource Page

Leaked Trade Negotiation Texts and Analysis

Find country-specific news, analyses and other resources here. Translations available in Spanish and Vietnamese.
courtesy of mjtmail
The TPP is being negotiated behind closed doors with the negotiation text kept secret from the public. Find leaked texts and analyses here.

Letters and Statements

External Resources

 Find letters sent by civil society organizations to their governments and statements on the TPP here.
Explore the websites of partner organizations to find out more about the TPP.

Back to Access to Medicines Home Page

Copyright © 2013 Public Citizen. All rights reserved. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation.
  Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.